Lilly’s Mounjaro Enters China’s State Insurance System
Eli Lilly achieved a major market access milestone after Mounjaro was officially added to China’s national medical insurance list for diabetes treatment, dramatically improving affordability and penetration prospects across the country. The inclusion allows millions of Chinese patients with type 2 diabetes to access tirzepatide at reimbursed prices for the first time, accelerating domestic adoption. The decision also strengthens Lilly’s competitive position against Novo Nordisk in the world’s largest diabetes market. Industry analysts view the move as a turning point for high-end metabolic biologics in China’s reimbursement system, signaling a broader willingness to cover premium innovation.
You May Interested In
High Quality β-Nicotinamide adenine dinucleotide CAS 53-84-9 NADwith ready stock and best price
$3/UNIT FOB
2026-10-16
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
EU Low-Value Parcel Rules Could Disrupt Chemical Sample Flows
-
EU May Build Industry-Level Trade Barriers Against Chinese Chemicals
-
What Can $3.4 Billion Buy? Shin-Etsu Chemical’s Answer: Upstream Control of PVC
-
EU Greenlights Four GM Crops—But Only at the Border
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
Domo Chemicals’ German Subsidiary Insolvencies: Energy Costs, Weak Demand and Chinese Nylon Competition
-
Carbon Fiber’s Price Surge Signals a New Era of Strategic Value—and Supply Tension
-
Sherwin-Williams Surpasses $100 Billion in Market Cap: Is This the ‘Apple Moment’ for Paint, or America’s Industrial ‘One Hundred Years of Solitude’?
-
The Carbon Tollbooth Is Open: EU’s CBAM Ushers in a New Era of Climate-Linked Trade
-
“Anti-Overcapacity” Backfires: China’s Chemical Industry Trapped in a Hell of Its Own Making—and Global Pushback
Recommend Reading
-
![FDA Grants Accelerated Approval to Bristol Myers Squibb’s ZENBEXUS, Launching First CELMoD Therapy in Multiple Myeloma]()
FDA Grants Accelerated Approval to Bristol Myers Squibb’s ZENBEXUS, Launching First CELMoD Therapy in Multiple Myeloma
-
![FDA Approves Lantheus’ TAUKLARIFY for Alzheimer’s Tau PET Imaging]()
FDA Approves Lantheus’ TAUKLARIFY for Alzheimer’s Tau PET Imaging
-
![From Rust to Recharge: Novonix Ignites America’s Graphite Independence with Twin Mega-Plants in Chattanooga]()
From Rust to Recharge: Novonix Ignites America’s Graphite Independence with Twin Mega-Plants in Chattanooga
-
![“Fake Fame” in a Forgotten Dock: Chinese Authorities Bust $100,000 Counterfeit Building Materials Ring]()
“Fake Fame” in a Forgotten Dock: Chinese Authorities Bust $100,000 Counterfeit Building Materials Ring
-
![Asian Paints Dives Deeper into the Desert: Unveils Second UAE Plant to Dominate GCC Coatings Market]()
Asian Paints Dives Deeper into the Desert: Unveils Second UAE Plant to Dominate GCC Coatings Market
-
![EU Set to Seek Import Quotas on PET, Epoxy Resins and Fibreglass as Trade Curbs Reach Chemicals]()
EU Set to Seek Import Quotas on PET, Epoxy Resins and Fibreglass as Trade Curbs Reach Chemicals
-
![Premium Global Chemical Sourcing Requests (13-16Aug, 2026)]()
Premium Global Chemical Sourcing Requests (13-16Aug, 2026)
-
![Cost Advantages Support, Polyester Staple Fiber Prices Remain on an Upward Trend]()
Cost Advantages Support, Polyester Staple Fiber Prices Remain on an Upward Trend
-
![South Korea and Japan Launch Energy Supply Chain Cooperation as Hormuz Risks Grow]()
South Korea and Japan Launch Energy Supply Chain Cooperation as Hormuz Risks Grow
-
![Crude oil remains in negative territory, another round of retail fuel price cuts in China]()
Crude oil remains in negative territory, another round of retail fuel price cuts in China
